Free Trial
NASDAQ:MLYS

Mineralys Therapeutics (MLYS) Stock Price, News & Analysis

Mineralys Therapeutics logo
$16.78 +0.61 (+3.77%)
Closing price 04:00 PM Eastern
Extended Trading
$16.35 -0.43 (-2.56%)
As of 06:38 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

About Mineralys Therapeutics Stock (NASDAQ:MLYS)

Key Stats

Today's Range
$16.28
$17.08
50-Day Range
$8.76
$16.87
52-Week Range
$8.24
$18.38
Volume
1.34 million shs
Average Volume
332,564 shs
Market Capitalization
$1.05 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$27.00
Consensus Rating
Buy

Company Overview

Mineralys Therapeutics, Inc., a clinical-stage biopharmaceutical company that develops therapies for the treatment of hypertension and chronic kidney diseases. It clinical-stage product candidate is lorundrostat, a proprietary, orally administered, highly selective aldosterone synthase inhibitor for the treatment of cardiorenal conditions affected by abnormally elevated aldosterone. The company was formerly known as Catalys SC1, Inc. and changed its name to Mineralys Therapeutics, Inc. in May 2020. The company was incorporated in 2019 and is headquartered in Radnor, Pennsylvania.

Remove Ads

Mineralys Therapeutics Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
57th Percentile Overall Score

MLYS MarketRank™: 

Mineralys Therapeutics scored higher than 57% of companies evaluated by MarketBeat, and ranked 391st out of 940 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Mineralys Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 4 buy ratings, no hold ratings, and no sell ratings.

  • Amount of Analyst Coverage

    Mineralys Therapeutics has only been the subject of 3 research reports in the past 90 days.

  • Read more about Mineralys Therapeutics' stock forecast and price target.
  • Earnings Growth

    Earnings for Mineralys Therapeutics are expected to decrease in the coming year, from ($4.23) to ($4.48) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Mineralys Therapeutics is -4.61, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Mineralys Therapeutics is -4.61, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    Mineralys Therapeutics has a P/B Ratio of 4.37. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

  • Read more about Mineralys Therapeutics' valuation and earnings.
  • Percentage of Shares Shorted

    8.18% of the float of Mineralys Therapeutics has been sold short.
  • Short Interest Ratio / Days to Cover

    Mineralys Therapeutics has a short interest ratio ("days to cover") of 4.
  • Change versus previous month

    Short interest in Mineralys Therapeutics has recently increased by 14.86%, indicating that investor sentiment is decreasing significantly.
  • Dividend Yield

    Mineralys Therapeutics does not currently pay a dividend.

  • Dividend Growth

    Mineralys Therapeutics does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    8.18% of the float of Mineralys Therapeutics has been sold short.
  • Short Interest Ratio / Days to Cover

    Mineralys Therapeutics has a short interest ratio ("days to cover") of 4.
  • Change versus previous month

    Short interest in Mineralys Therapeutics has recently increased by 14.86%, indicating that investor sentiment is decreasing significantly.
  • News Sentiment

    Mineralys Therapeutics has a news sentiment score of 0.74. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 11 news articles for Mineralys Therapeutics this week, compared to 3 articles on an average week.
  • Search Interest

    3 people have searched for MLYS on MarketBeat in the last 30 days. This is an increase of 50% compared to the previous 30 days.
  • MarketBeat Follows

    1 people have added Mineralys Therapeutics to their MarketBeat watchlist in the last 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Mineralys Therapeutics insiders have bought 9,597.48% more of their company's stock than they have sold. Specifically, they have bought $25,599,996.00 in company stock and sold $263,986.00 in company stock.

  • Percentage Held by Insiders

    33.24% of the stock of Mineralys Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.

  • Percentage Held by Institutions

    84.46% of the stock of Mineralys Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

  • Read more about Mineralys Therapeutics' insider trading history.
Receive MLYS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Mineralys Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

MLYS Stock News Headlines

Elon Musk is helping print “new gold”
MIT scientists just developed a brand-new metal… A metal that’s shaping up to be, not only the biggest breakthrough in artificial intelligence… but in human technology. It’s so valuable that some are referring to it as the “new gold”.
See More Headlines

MLYS Stock Analysis - Frequently Asked Questions

Mineralys Therapeutics' stock was trading at $12.31 on January 1st, 2025. Since then, MLYS shares have increased by 36.3% and is now trading at $16.78.
View the best growth stocks for 2025 here
.

Mineralys Therapeutics, Inc. (NASDAQ:MLYS) released its quarterly earnings data on Wednesday, February, 12th. The company reported ($0.98) earnings per share (EPS) for the quarter, beating the consensus estimate of ($1.00) by $0.02.

Mineralys Therapeutics (MLYS) raised $180 million in an IPO on Friday, February 10th 2023. The company issued 12,000,000 shares at $14.00-$16.00 per share.

Top institutional shareholders of Mineralys Therapeutics include Orbimed Advisors LLC (3.24%), Vanguard Group Inc. (2.88%), Adams Street Partners LLC (2.27%) and Millennium Management LLC (2.21%). Insiders that own company stock include Brian Taylor Slingsby, Samsara Biocapital Gp, Llc, Ra Capital Management, LP, Hbm Healthcare Investments (Ca, Jon Congleton, Adam Scott Levy and David Malcom Rodman.
View institutional ownership trends
.

Shares of MLYS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Mineralys Therapeutics investors own include Tesla (TSLA), Advanced Micro Devices (AMD), JPMorgan Chase & Co. (JPM), Meta Platforms (META), NVIDIA (NVDA), Netflix (NFLX) and Alphabet (GOOG).

Company Calendar

Last Earnings
2/12/2025
Today
3/25/2025
Next Earnings (Estimated)
5/08/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:MLYS
Fax
N/A
Employees
28
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$27.00
High Stock Price Target
$30.00
Low Stock Price Target
$24.00
Potential Upside/Downside
+60.9%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
4 Analysts

Profitability

Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
$-177,810,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Price / Cash Flow
N/A
Book Value
$3.84 per share
Price / Book
4.37

Miscellaneous

Free Float
33,271,000
Market Cap
$1.05 billion
Optionable
Optionable
Beta
1.50
2025 Gold Forecast: A Perfect Storm for Demand Cover

Unlock the timeless value of gold with our exclusive 2025 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.

Get This Free Report

This page (NASDAQ:MLYS) was last updated on 3/25/2025 by MarketBeat.com Staff
From Our Partners